

## Who we are



*We are a science-led global healthcare company with a special purpose: to help people do more, feel better and live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.*

## What we do



*We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible with our three global businesses, scientific and technical know-how and talented people.*

## How we do it



*Everyone at GSK is focused on 3 priorities – Innovation, Performance, Trust*

***Innovation:*** *We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.*

***Performance:*** *We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.*

***Trust:*** *We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer.*

***Our values and expectations*** *are at the heart of everything we do and help define our culture – so that together we can deliver extraordinary things for our patients and consumers and make GSK a brilliant place to work.*

# GSK in Canada Fast Facts

**Heritage** GSK's history in Canada dates to 1902

**Employees** Employs over 2,500 full time employees across the country, providing a salary injection of approx. \$690 million into the Canadian economy.



**Locations** Two divisional headquarters in Mississauga, Ontario and Laval, Quebec, and an administrative office in Quebec City.

**Manufacturing** Two manufacturing facilities



1. Mississauga (Ontario) manufacturing site produces approximately 50 different products, exporting 90% to more than 100 markets worldwide.
2. Ste-Foy (Quebec) vaccine manufacturing site currently produces a majority share of Canada's seasonal influenza vaccine and is responsible for the domestic supply of the country's pandemic influenza vaccine requirements.

**Research & Development** Invested more than \$2 billion since 2001 in Canadian pharmaceutical and vaccines R&D, ranking GSK among the top 10 contributors to R&D in Canada across all industries.



In 2018 alone, GSK in Canada invested over \$70 million to R&D.

Helped establish 22 Research Chairs in Faculties of Medicine and Pharmacy at Canadian universities in respiratory healthcare, vaccinology, HIV, oncology, and management of chronic disease amongst others.

In 2018, invested over \$ 15 million into 54 active clinical trials across Canada involving 2,793 active subjects.

Supported 15 Investigator Sponsored Studies with physicians across Canada in 2018.

In 2018, sponsored approx. 30 Canadian research projects, focused on health economics and outcomes research to support the scientific understanding of our medicines and vaccines.

**Product Portfolio**



Helping to transform the treatment of asthma, COPD and other respiratory diseases, we have a full, broad and innovative respiratory portfolio spanning established and new compounds and delivery systems.



We have the most comprehensive vaccines portfolio in the industry, helping to protect children, teenagers, adults & elderly and travellers against diseases like whooping cough, hepatitis, meningitis and shingles.



Spanning across six categories (pain relief, respiratory, digestive health, oral health, nutrition and skin health), we produce some of Canada's best-loved consumer healthcare brands including VOLTAREN, NEOCITRAN, TUMS, SENSODYNE, and BUCKLEY'S.

**Community Investment**



An Imagine Canada Caring Company since 1990, GSK contributes over 1% of pre-tax profits annually to initiatives in health and local community organizations.

A contributor to Health Partners International of Canada (HPIC) since 1994, we have provided \$30 million worth of product donations and over \$1 million in grants for the provision of medical relief to vulnerable communities globally. In 2018, our support of HPICs international relief efforts contributed to the provision of over 500 Humanitarian Medical Kits and the treatment of almost one million people.

Proud partner with the Canadian Hospice Palliative Care Association (CHPCA) for more than 20 years, contributing over \$3 million to support the hospice palliative care movement in Canada.

Initiated in 2013, GSK's partnership with Save the Children aims to help save one million children's lives. Employees from around the world have raised an impressive £3.3 million (approx. \$5.6 million CDN), which is matched by GSK. In 2017, our employees created the grassroots 'Ride4Kids' fundraising bike ride to raise money for Save the Children. Since its inception, Ride4Kids has raised over \$300,000 for Save the Children. Each year, funds raised were matched by GSK.

In 2019, GSK donated \$75,000 to Save the Children to help Indigenous children affected by the ongoing housing and health emergency in Cat Lake, Northern Ontario.

**Ways of Working**



Among a group of 10 Innovative Medicines Canada members who, since 2017, have voluntarily agreed to publicly report aggregate payments made to healthcare professionals and healthcare organizations. Despite the lack of disclosure requirements in Canada, GSK is proud to be leaders in expanding our reporting of payments and will begin individual level reporting in June 2020 for transfers of value made to Healthcare professionals throughout 2019.

**Environmental Sustainability**



Completed in 2012, GSK's administrative building in Laval, Quebec received Leadership in Energy and Environmental Design (LEED) Gold certification from the Canada Green Building Council. GSK Canada supports the Medications Return Program at pharmacies throughout the country.

GSK supports provincial stewardship associations across the country to ensure our packaging components can be recycled through Local Blue Box programs.

Raised the set building temperature at GSK's Mississauga head office 1.5 degrees during the summer months, reducing demand on the utility grid and resulting in savings of 102,000 kWh. This is equivalent to reducing greenhouse gas emissions of 15 cars for a year.

Since 2017, GSK has converted conventional to LED light bulbs, which consume up to 40% less energy than florescent light and over 90% less than traditional incandescent light bulbs.

In October 2018, GSK Canada launched a Centralized Waste program involving the removal of individual waste containers from offices to promote environmental consciousness and reduce our contribution to landfills.